AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
Want to see IN:ASTRAZEN full AI Analyst Report?
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹7,630.00 - ₹10,653.05
Previous CloseN/A
Volume65.42K
Average Volume (3M)602.00
Market Cap
₹212.54B
Enterprise Value₹210.68B
Total Cash (Recent Filing)₹4.10B
Total Debt (Recent Filing)₹347.90M
Price to Earnings (P/E)173.1
Beta0.78
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)13.04
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio-6.48
Price to Book (P/B)27.56
Price to Sales (P/S)12.39
P/FCF Ratio333.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue growth more than doubled top-line size, indicating durable demand across therapy areas and successful commercialization of branded prescription medicines in India. This scale supports long-term market presence, bargaining power with channels, and reinvestment capacity.
Strong Cash GenerationImproved operating cash conversion (OCF to Net Income 0.56) and material free-cash metrics imply reliable internal funding for operations and capex. Durable cash generation reduces dependence on external financing and supports steady investment in sales, launches, and working capital.
Low Financial LeverageMinimal leverage and a rising equity base (strong equity ratio) provide balance-sheet flexibility to absorb shocks and finance growth. Low debt servicing requirements improve resilience, allow selective M&A or investment, and lower refinancing risk over the medium term.
Bears Say
Declining Return On EquityA multi-year drop in ROE signals weaker efficiency in converting equity into profits. If persistent, it may indicate reduced operating leverage, margin pressure or investments not yielding proportional returns, which can limit long-term shareholder value creation unless reversed.
Margin CompressionMaterial decline in net margin suggests rising operating costs or mix shifts toward lower-margin products. Sustained margin compression could erode cash available for R&D, marketing, and expansion, making profitability more sensitive to revenue volatility over the medium term.
Rising Total LiabilitiesGrowing absolute liabilities, even with low leverage ratios, raise long-term obligations and liquidity demands. If liabilities continue to climb faster than operating cash or equity, the company may face increased financing costs or constrained flexibility for strategic initiatives.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹7630.00 and its highest was ₹10653.05 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹212.54B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is May 27, 2026 which is in 29 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on Feb 11, 2026. The company reported ₹13.036 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.036.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.35%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹13.036 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Alkem Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―